Skip to main content

Table 1 Composition and characteristics of the HCC antigen peptides pool

From: Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy

No. Antigen Overexpressed in HCC Clinical trialsa References
1 hTERT + OC, BC, PC, melanoma, MM [8, 9]
2 p53 + (loss of function) LC, BC, OC, melanoma, PC, HNSCC, CRC, CC [10, 11]
3 Survivin + HCC, AML, ALL, OC, BC, PC, RCC, melanoma, MM, LC, EC, STS [1012]
4 NY-ESO-1 + HCC, SS, MM, melanoma, OC, LC, oesophageal cancer; sarcoma, BC, bladder carcinoma [8, 13]
5 CEA + CRC, LC, BC, GC, LM [14, 15]
6 CCND1 + RCC [16, 17]
7 c-MET + RCC, BC [17, 18]
8 RGS5 + RCC [17, 19]
9 MMP7 + RCC [17, 20]
10 VEGFR + Melanoma, RC, RCC [21]
11 AFP + HCC [8, 22]
12 GPC3 + HCC [23, 24]
13 HBV core antigen + (when HBV+) [8, 17]
14 HBV DNA polymerase + (when HBV+)  
  1. hTERT human telomerase reverse transcriptase, CEA carcinoembryonic antigen, CCND1 cyclin D1, MET HGF-hepatocyte growth factor receptor, RGS5 regulators of G protein signaling 5, MMP7 matrix metalloproteinase 7, VEGFR vascular endothelial growth factor receptor, AFP alpha fetoprotein, GPC3 glypican-3, OC ovarian cancer, BC breast cancer, PC pancreatic cancer, MM multiple myeloma, LC lung cancer, HNSCC head and neck squamous cell carcinoma, CRC colorectal cancer, CC cervical cancer, HCC hepatocellular carcinoma, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, RCC renal carcinoma, EC esophagus cancer, STS soft tissue sarcoma, SS synovial sarcoma, GC gastric cancer, LM liver metastases, RC renal cancer
  2. aOnly the clinical trials of cancer immunotherapies such as DC vaccines, ACT and peptides vaccines were indicated